News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
09-Dec-2009 - Allon Therapeutics Inc. announced that the results of a Phase IIa clinical trial indicate that the Company’s lead neuroprotective drug candidate davunetide achieved measurable positive treatment effects in schizophrenia patients with cognitive impairment. The trial was managed by TURNS (Treatment ...
16-Apr-2009 - Allon Therapeutics Inc. announced that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by the issuance of a U.S. patent covering the chemical composition of two component peptides and covering their use in drugs to ...
27-May-2008 - Allon Therapeutics Inc. announced it has completed the randomized portion of its Phase II human clinical trial evaluating the Company's product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery. The Company ...
05-Oct-2007 - Allon Therapeutics Inc. announced that enrolment is complete in the Phase II clinical trial evaluating Allon's drug candidate AL-108 as a treatment for Alzheimer's disease. This trial has progressed ahead of schedule and is expected to be the first of Allon's three Phase II efficacy trials to ...
17-Sep-2007 - Allon Therapeutics Inc. announced that enrolment has commenced in a Phase II clinical trial evaluating Allon's product AL-108 as a treatment for schizophrenia-related cognitive impairment. This study is being conducted in collaboration with TURNS (Treatment Units for Research on Neurocognition ...
09-Aug-2007 - Allon Therapeutics Inc. announced that in collaboration with TURNS (Treatment Units for Research on Neurocognition and Schizophrenia) and with support from the National Association for Research in Schizophrenia and Affective Disorders (NARSAD) they will add an imaging-biomarker component to the ...
14-Jun-2007 - Allon Therapeutics Inc. announced that it has been granted a US patent covering additional composition of matter for the products in the ADNP platform, which broadens the intellectual property of Allon's patent portfolio. Gordon McCauley, President and CEO of Allon, said these claims ...
26-Apr-2007 - Allon Therapeutics Inc. released new data confirming that the Company's product AL-309 has robust oral bioavailability in preclinical studies. This new data also shows that AL-309 enters the brain and that effective concentrations can be detected for extended periods of time. This information ...
20-Jun-2005 - Allon Therapeutics Inc., The Neuro Protection Company(TM), announced that a Phase Ia human clinical trial of the company's first product AL-108 has demonstrated that a single dose administered at up to 15 milligrams was safe and well tolerated in healthy adults. AL-108 is being developed as a ...
06-Jun-2005 - Allon Therapeutics Inc., The Neuro Protection Company(TM), announced that new preclinical animal studies have confirmed that its lead product candidates AL-108 and AL-208 penetrate the blood brain barrier and reach their target therapeutic areas in the central nervous system. The blood-brain ...
© 1997-2024 LUMITOS AG, All rights reserved